Skip to main content
Deutsch

Search

  1. Home
  2. Search

Webseiten-Inhalte

Immune marker analysis: size of tumour tissue area crucial for survival prognosis ... activity in the tumour compared to tissue-sparing punch biopsies. A team led by the visceral surgeon Elisabeth S. Gruber and the molecular pathologist Lukas Kenner from MedUni Vienna demonstrated these findings by immunohistochemical investigation of tumour tissue of rectal cancer patients. With the second... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2020/news-im-maerz/immune-marker-analysis-size-of-tumour-tissue-area-crucial-for-survival-prognosis/medicine-science/?L=3
Immune marker analysis: size of tumour tissue area crucial for survival prognosis ... activity in the tumour compared to tissue-sparing punch biopsies. A team led by the visceral surgeon Elisabeth S. Gruber and the molecular pathologist Lukas Kenner from MedUni Vienna demonstrated these findings by immunohistochemical investigation of tumour tissue of rectal cancer patients. With the second... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2020/news-im-maerz/immune-marker-analysis-size-of-tumour-tissue-area-crucial-for-survival-prognosis/?tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=11&cHash=4eec7e5e56ced03058efa23e78c6868c
Immune marker analysis: size of tumour tissue area crucial for survival prognosis ... activity in the tumour compared to tissue-sparing punch biopsies. A team led by the visceral surgeon Elisabeth S. Gruber and the molecular pathologist Lukas Kenner from MedUni Vienna demonstrated these findings by immunohistochemical investigation of tumour tissue of rectal cancer patients. With the second... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2020/news-im-maerz/immune-marker-analysis-size-of-tumour-tissue-area-crucial-for-survival-prognosis/?tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=2&cHash=f7b8aacc5325df0b91e534c46b12ab37
Neuroblastoma: improved treatment prospects in future ...All News – Medicine & Science (Vienna, 03 December 2019) Neuroblastoma is a rare form of malignant tumour, primarily affecting children under the age of six. A research team led by molecular pathologist Lukas Kenner from MedUni Vienna's Department of Pathology has now... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2019/news-im-dezember-2020/neuroblastoma-improved-treatment-prospects-in-future/?L=3
Neuroblastoma: improved treatment prospects in future ...All News – Medicine & Science (Vienna, 03 December 2019) Neuroblastoma is a rare form of malignant tumour, primarily affecting children under the age of six. A research team led by molecular pathologist Lukas Kenner from MedUni Vienna's Department of Pathology has now... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2019/news-im-dezember-2020/neuroblastoma-improved-treatment-prospects-in-future/medicine-science/?L=3
Researcher of the MedUni Vienna ...MuDr. Kilian Kluge Department of Biomedical Imaging and Image-guided Therapy (Clinical Division of Nuclear Medicine)Position: Doctor-in-training ORCID: 0000-0002-4224-7314T +43 1 40400 58739 kilian.kluge@meduniwien.ac.at Research group(s) Christian Doppler Laboratory for Applied MetabolomicsHead: Lukas KennerResearch Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.Members: Marko Grahovac David Haberl Lukas Kenner Kilian Kluge Marzieh Nejabat Jing Ning Research interests My research is primarily focused on understanding the connection between (epi)genetic tumor subtypes and their destinct functional imaging phenotypes by contextualizing... https://www.meduniwien.ac.at/web/forschung/researcher-profiles/researcher-profiles/detail/?res=kilian__kluge&cHash=c2bde58355e86017ab91c890e829af2f
Researcher of the MedUni Vienna ...MuDr. Kilian Kluge Department of Biomedical Imaging and Image-guided Therapy (Clinical Division of Nuclear Medicine)Position: Doctor-in-training ORCID: 0000-0002-4224-7314T +43 1 40400 58739 kilian.kluge@meduniwien.ac.at Research group(s) Christian Doppler Laboratory for Applied MetabolomicsHead: Lukas KennerResearch Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.Members: Marko Grahovac David Haberl Lukas Kenner Kilian Kluge Marzieh Nejabat Jing Ning Research interests My research is primarily focused on understanding the connection between (epi)genetic tumor subtypes and their destinct functional imaging phenotypes by contextualizing... https://www.meduniwien.ac.at/web/forschung/researcher-profiles/researcher-profiles/detail/?res=kilian__kluge&cHash=0016747d495c91eb72d200e08efcc3f5
Researcher of the MedUni Vienna ...MuDr. Kilian Kluge Department of Biomedical Imaging and Image-guided Therapy (Clinical Division of Nuclear Medicine)Position: Doctor-in-training ORCID: 0000-0002-4224-7314T +43 1 40400 58739 kilian.kluge@meduniwien.ac.at Research group(s) Christian Doppler Laboratory for Applied MetabolomicsHead: Lukas KennerResearch Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.Members: Marko Grahovac David Haberl Lukas Kenner Kilian Kluge Marzieh Nejabat Jing Ning Research interests My research is primarily focused on understanding the connection between (epi)genetic tumor subtypes and their destinct functional imaging phenotypes by contextualizing... https://www.meduniwien.ac.at/web/forschung/researcher-profiles/researcher-profiles/detail/index.php?id=688&res=kilian__kluge
Researcher of the MedUni Vienna ...MuDr. Kilian Kluge Department of Biomedical Imaging and Image-guided Therapy (Clinical Division of Nuclear Medicine)Position: Doctor-in-training ORCID: 0000-0002-4224-7314T +43 1 40400 58739 kilian.kluge@meduniwien.ac.at Research group(s) Christian Doppler Laboratory for Applied MetabolomicsHead: Lukas KennerResearch Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.Members: Marko Grahovac David Haberl Lukas Kenner Kilian Kluge Marzieh Nejabat Jing Ning Research interests My research is primarily focused on understanding the connection between (epi)genetic tumor subtypes and their destinct functional imaging phenotypes by contextualizing... https://www.meduniwien.ac.at/web/forschung/researcher-profiles/researcher-profiles/index.php?id=688&res=kilian__kluge
Researcher of the MedUni Vienna ...MuDr. Kilian Kluge Department of Biomedical Imaging and Image-guided Therapy (Clinical Division of Nuclear Medicine)Position: Doctor-in-training ORCID: 0000-0002-4224-7314T +43 1 40400 58739 kilian.kluge@meduniwien.ac.at Research group(s) Christian Doppler Laboratory for Applied MetabolomicsHead: Lukas KennerResearch Area: We investigate ways to better characterize tumors using non-invasive imaging techniques. This is important because tumours are constantly changing through mutations. In this way, an individual therapy should be possible and its success should be continuously monitored.Members: Marko Grahovac David Haberl Lukas Kenner Kilian Kluge Marzieh Nejabat Jing Ning Research interests My research is primarily focused on understanding the connection between (epi)genetic tumor subtypes and their destinct functional imaging phenotypes by contextualizing... https://www.meduniwien.ac.at/web/forschung/researcher-profiles/researcher-profiles/detail/?name=Kilian%20_Kluge&res_id=979&cHash=c39e970a8d18955a9e03d21559118f83